Abstract 4340
Background
Pulmonary embolism (PE) is a common condition in patients with cancer, having a wide spectrum of clinical presentation (from acute life-threatening to truly asymptomatic incidental events). The aim of this study was to assess the prognostic relevance of the variable ‘setting’ (hospital-acquired vs. outpatient) at PE diagnosis.
Methods
Multicenter observational ongoing registry of consecutive patients with cancer-associated PE (2005-2018) including incidental and acute symptomatic events. The main outcome measured was the rate of overall and PE-specific 30-day mortality. Secondary outcomes were: rates of 30-day major bleeding (MB) and venous thromboembolism (VTE) recurrence.
Results
We included a total of 617 patients (61.6% male; median age 65 + 11.4 years; range 19-91 years) including N = 522 (85%) outpatients and N = 95 (15%) inpatients at PE diagnosis. The most frequent primary tumors were: lung 32%, colorectal 14%, urologic 13%, upper GI 12%, breast 9%, gynecologic 6% and other 9%). Most of the patients (79%) had metastatic cancer and nearly half (47%) were receiving chemotherapy.The PE was incidentally found in 54% of the cases. Overall 30-day mortality occurred in 95 patients (15% of the cohort), being greater in inpatients compared to outpatients (30% vs. 13%; p < 0.0001). Only 13 patients presented PE-related mortality (3% of the cohort), with no significant differences according to the setting at PE diagnosis (3.2% in inpatients vs. 1.7% in outpatients; p = 0.352). Similarly, there were no differences in 30-day MB (7.4% in inpatients vs. 4.4% in outpatients; p = 0.217) or VTE recurrence (4.2% in inpatients vs. 3.3% in outpatients; p = 0.637) according to the setting at PE diagnosis.
Conclusions
Hospital-acquired PE in cancer patients was associated with a greater overall 30-day mortality compared to outpatients at PE diagnosis. This finding may be relevant for the development of PE risk-assessment models in this setting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hospital Clínic de Barcelona.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2432 - Retrospective comparative study of the efficacy and safety in docetaxel and ramucirumab combination chemotherapy with or without previous immune checkpoint inhibitor treatment.
Presenter: Daijiro Harada
Session: Poster Display session 1
Resources:
Abstract
2791 - Efficacy of weekly paclitaxel-bevacizumab combination in advanced non squamous non-small cell lung cancer (NSCLC) : a retrospective multicentric study.
Presenter: Geoffroy Bilger
Session: Poster Display session 1
Resources:
Abstract
2916 - Post progression survival for patients treated with docetaxel/nintedanib in the SENECA trial
Presenter: Enrica Capelletto
Session: Poster Display session 1
Resources:
Abstract
1427 - Final results of randomized phase II trial of metronomic vs weekly oral vinorelbine (OV) as first-line chemotherapy (CT) in advanced NSCLC patients unfit to platinum-based CT (P-CT): Tempo-Lung EudraCT Number: 2014-003859-61
Presenter: Dariusz Kowalski
Session: Poster Display session 1
Resources:
Abstract
3789 - Pioglitazone and clarithromycin combined with metronomic low-dose chemotherapy versus nivolumab in patients with advanced non–small-cell lung cancer treated in 2nd-line and beyond: Outcomes from a randomized phase II trial (ModuLung)
Presenter: Daniel Heudobler
Session: Poster Display session 1
Resources:
Abstract
1519 - Predicting Chemotherapy Toxicity in Elderly Patients with Advanced Non-small Cell Lung Cancer: A Prospective Multicenter Study of the National Hospital Organization in Japan
Presenter: Masaki Kanazu
Session: Poster Display session 1
Resources:
Abstract
1874 - A prospective phase II trial of carboplatin (CBDCA) and nab-paclitaxel (nabPTX) for advanced non-small cell lung cancer (NSCLC) with interstitial lung disease (ILD)
Presenter: Toshiyuki Harada
Session: Poster Display session 1
Resources:
Abstract
3819 - Weekly Epirubicin as palliative treatment in elderly patients with malignant pleural mesothelioma.
Presenter: Paola Candido
Session: Poster Display session 1
Resources:
Abstract
3390 - Survival Prolongation by Rationale INnovative Genomics (SPRING): An international WIN Consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates.
Presenter: Benjamin Solomon
Session: Poster Display session 1
Resources:
Abstract
5069 - Preliminary results from phase 1b study of spartalizumab plus chemotherapy for advanced non-small cell lung cancer (NSCLC)
Presenter: Armando Santoro
Session: Poster Display session 1
Resources:
Abstract